About liver diseases
Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Hepatitis is the largest segment among these diseases, of which hepatitis C is the biggest and fastest growing segment. The liver diseases caused by viral infections, alcoholism, obesity, diabetes, among many other reasons. Some of the diseases are not curable such as liver cirrhosis or non-alcoholic fatty liver disease, and are usually not diagnosed early. This leads to the substantial damage of the liver, which proves to be life-threatening. Some types of hepatitis are preventable or treatable by using vaccines and indicated drugs.
Technavio's analysts forecast the global liver diseases therapeutics market to grow at a CAGR of 15.61% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global liver diseases therapeutics market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of liver diseases. Based on disease indication, the market is segmented as follows:
Press Release
Technavio Announces the Publication of its Research Report – Global Liver Diseases Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Liver Diseases Therapeutics Market: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck
Other Prominent Vendors in the market are: Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, and Zafgen.
Commenting on the report, an analyst from Technavio’s team said: “The early detection of infections is important in reducing disease progression. For instance, the early screening and diagnosis of hepatitis C and B infections can prevent or reduce the extent of liver damage. Various government and nongovernmental organizations have been organizing awareness campaigns, seminars, summits, and fundraising events to educate people about the diseases and therapeutic measures available.”
According to the report, a significant number of approved pharmacotherapeutic products available in the market fail to completely cure hepatitis, liver cancer, cirrhosis, and nonalcoholic fatty liver disease. In addition, most of the drugs have severe side effects such as nausea and bone marrow suppression, resulting in noncompliance among individuals with liver diseases. Apart from this, the availability of hepatitis vaccines is also low in many regions due to limited public awareness of the disease and the high cost of therapeutics. All these factors further deepen the unmet medical needs of the market, presenting vendors with an opportunity to develop therapies that have better safety and efficacy profiles than available approved drugs.
Further, the report states that patent expiries of approved drugs, such as Baraclude, have led to, and will continue to lead to, the entry of their generic forms, which are less expensive. Inadequate vaccine coverage, especially in low-income countries, also negatively affects market growth.
Companies Mentioned
F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Achillion Pharmaceuticals, AbbVie, Advinus, Angion Biomedica, AstraZeneca, Bayer, BiOrion, Boehringer Ingelheim , Bristol-Myers Squibb, Celsion, Conatus, Digna Biotech, Dynavax Technologies, Eli Lilly, Galectin Therapeutics, Genfit, GenKyoTex, Isis Pharmaceuticals, Janssen Pharmaceuticals, La Jolla Pharmaceutical, LG Life Sciences, Kaketsuken, Mitsubishi Tanabe Pharma, Nitto Denko, Novartis, Onyx Pharmaceuticals (a subsidiary of Amgen), Phenex Pharmaceuticals, Promedior, Promethera Biosciences, ProMetic Life Sciences, Raptor Pharmaceuticals, Shenzhen Kangtai Biological Products, TCM Biotech, Tobira Therapeutics, VBL Therapeutics, Verva Pharmaceuticals, Virobay, Zafgen.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook